FDA Approval of Onivyde Combination Expanded to First-Line Treatment in mPDAC

Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy. Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy.

Related Keywords

Julie Fleshman ,Drug Administration ,Pancreatic Cancer Action Network ,Healthday News ,